Treatment News : ICAAC: Once-Daily Isentress as Good as Twice-Daily?

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » September 2009

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


September 15, 2009

ICAAC: Once-Daily Isentress as Good as Twice-Daily?

People who switched from a protease inhibitor (PI) to Isentress (raltegravir) did well regardless of whether they switched to a once-daily or twice-daily dose of the drug, according to a study presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco and reported by the National AIDS Treatment Advocacy Project (NATAP).

Isentress is currently the only approved drug in a class of HIV drugs called integrase inhibitors. It is a potent drug that is approved for twice-daily use in both people who are heavily treatment experienced and those who are starting treatment for the first time.

To determine whether Isentress could be used twice daily, researchers conducted a small pilot study involving 125 people who were currently stable on a regimen that included a PI. Sixty-three people who had been taking a once-daily PI exchanged the PI for once-daily Isentress, while 62 people who had been taking a twice-daily PI switched to twice-daily Isentress.

Though the two groups were similar in many respects, people in the once-daily group were somewhat older, were more than twice as likely to also be infected with hepatitis C virus (HCV) and had higher bilirubin levels.

During an average follow-up of 15 months, four people virologically failed in the twice-daily group and one failed in the once-daily group. CD4 levels were the same in both groups. Safety and tolerability were essentially the same regardless of the Isentress dosing schedule; however, there was a trend toward improved quality of life in the once-daily group.

Search: Isentress, raltegravir, integrase inhibitor, ICAAC, once-daily

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (2 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.